Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 53

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 53
---
 breadth of claims that it will allow
in biotechnology patents.

The patent applications we file, including applications
that will follow the filing of provisional patents, may not issue as patents or the claims of any issued patents may not afford meaningful
protection for our technologies, tests, or products. In addition, patents issued to us or to any future licensors may be challenged and
subsequently narrowed, invalidated, or circumvented. Patent litigation is widespread in the biotechnology industry and could harm our
business. Litigation might be necessary to protect our patent position or to determine the scope and validity of third-party proprietary
rights, and we may not have the required resources to pursue such litigation or to protect our patent rights.

Although we have executed assignment of invention
agreements with current scientific and technical employees and in the future will require our scientific and technical employees and consultants
to enter into broad assignment of invention agreements, and require all of our employees, consultants, and corporate partners with access
to proprietary information to enter into confidentiality agreements, these agreements may not be honored.

Diagnostic tests and therapeutic products we develop could be subject to infringement claims asserted by others.

We cannot assure that diagnostic tests and therapeutic
products based on our patents or intellectual property that we license from others will not be challenged by a third-party claiming infringement
of its proprietary rights. If we are not able to successfully defend patents that may be issued to us, that we may acquire, or that we
may license in the future, we may have to pay substantial damages or licensing fees, possibly including treble damages, for past infringement.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming, and ultimately unsuccessful.

Competitors may infringe our issued patents or other
intellectual property. To counter infringement or unauthorized use, we intend to file infringement claims, which can be expensive and
time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging
that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours
is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly, or refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation
proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly